News Lynparza gets OK for use in prostate, breast cancers on NHS AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed
News Merck drops last phase 3 Keytruda trial in prostate cancer KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.
News J&J gets restricted label for PARP drug Akeega in EU Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.
Oncology Time to level the playing field for men with prostate cancer Prostate cancer affects not just patients, but their families too.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
News Roche finally drops curtain on AKT drug ipatasertib In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends